Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.
Biotech stocks may or may not be in a bubble, but investors are definitely worried about sky-high valuations.
Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.
Biogen shares are up on strong Alzheimer's drug data, but is the biotech bull market making investors forget about risk?
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biogen Idec's drug BIIB037 slowed cognitive decline and reduced brain plaques in Alzheimer's patients.
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.
Celgene will be starting phase III studies of mongersen in Crohn's disease -- designed to lead to the drug's approval -- by the middle of the year.
MannKind is facing a cash shortfall unless it can settle with debt holders by August.
When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.